Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
Tianmei Si,1,2 Jianmin Zhuo,3 Yu Feng,4 Huafei Lu,5 Di Hong,5 Lili Zhang51National Clinical Research Center for Mental Disorders & The Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People’s Republic of China; 2Peking University Institute of Menta...
Guardado en:
Autores principales: | Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang LL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6b9f26ff9faa4520b50ab464bab6b85b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021) -
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018) -
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
por: Mathews M, et al.
Publicado: (2020) -
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao JP, et al.
Publicado: (2017) -
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
por: Lambert M, et al.
Publicado: (2020)